Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Amortization of Deferred Charges (2017 - 2025)

Cryo Cell International (CCEL) has disclosed Amortization of Deferred Charges for 9 consecutive years, with $5165.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 1.99% to $5165.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $20822.0, a 1.95% decrease, with the full-year FY2025 number at $20822.0, down 1.95% from a year prior.
  • Amortization of Deferred Charges was $5165.0 for Q4 2025 at Cryo Cell International, down from $5192.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $19682.0 in Q1 2021 to a low of $591.0 in Q3 2022.
  • A 5-year average of $6818.8 and a median of $5360.0 in 2023 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: plummeted 95.23% in 2022, then soared 813.2% in 2023.
  • Cryo Cell International's Amortization of Deferred Charges stood at $9389.0 in 2021, then plummeted by 41.78% to $5466.0 in 2022, then decreased by 1.72% to $5372.0 in 2023, then decreased by 1.9% to $5270.0 in 2024, then dropped by 1.99% to $5165.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Amortization of Deferred Charges are $5165.0 (Q4 2025), $5192.0 (Q3 2025), and $5219.0 (Q2 2025).